Ac Immune SA ACIU
Annual
Quarterly
No annual revenue total was found in AC IMMUNE SA's SEC filings.
Ac Immune SA (ACIU) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
—
Operating cash flow
—
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
101.74M
+1.3% vs prior year
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ACIU (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Switzerland
- Headquarters
- 1015 Lausanne, Switzerland
- SEC filer status
- Accelerated filer
- SEC CIK
- 1651625
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Nov 4, 2026 | Nov 3, 2026 |
| 6-K | Current report (foreign issuer) | Oct 2, 2026 | Oct 2, 2026 |
| 6-K | Current report (foreign issuer) | Sep 23, 2026 | Sep 23, 2026 |
| 6-K | Current report (foreign issuer) | Sep 3, 2026 | Sep 3, 2026 |
| 6-K | Current report (foreign issuer) | Aug 20, 2026 | Aug 20, 2026 |
| 6-K | Current report (foreign issuer) | Aug 11, 2026 | Aug 11, 2026 |
All 313 Ac Immune SA SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.